Recently, HRoot Awards 2022 organized by HRoot, a leading HR media company in China, were announced. Hansoh Pharma was named to the "Best Employers in Greater China 2022" list for its outstanding employer brand image, professional HR management and excellent social responsibility practices.
HRoot Awards are the most authoritative, influential and credible HR awards in the Greater China region, recognizing outstanding management organizations, teams and leaders who are driving the industry. The naming of Hansoh Pharma to the "Best Employers in Greater China 2022" list this time fully reflects the high affirmation of the company's corporate culture, talent strategy, learning and development, and employee well-being, and is also an important guide and drive for the company's future sustainable and high-quality development.
Hansoh Pharma attaches great importance to the training of employees on their leadership, collaboration, execution, internal drive and strategic vision, and takes comprehensive measures to promote the deployment of innovative, international talents. The company has now established four R&D centers in Maryland, the United States and in Shanghai, Lianyungang and Changzhou, China, and built a large-scale, professional, fully capable global R&D team of 1,400+ people. Hansoh Pharma has successfully marketed 6 innovative drugs, and is conducting 40+ clinical trials on 25+ innovative drug projects at different clinical stages. The company has gradually established a global high-quality talent team, laying a solid foundation for accelerating the global drug R&D process and promoting China's pharmaceutical innovations to the world through people-oriented technological innovation.
Looking ahead, Hansoh Pharma will further uphold the corporate mission to create excellence in pharmaceuticals and enhance innovation in China, attract top talents and bring together high-quality resources, implement the sustainable development strategy, provide more high-quality innovative drugs that are accessible and affordable to patients worldwide, and contribute to the Healthy China 2030 Initiative.
